These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 34499744)

  • 1. Outcomes using direct-acting antiviral hepatitis-C treatment in older versus younger Veterans.
    Blanquicett CJ; Raavi T; Mirk A; Johnson TM; Jaglal M; Cartwright EJ
    J Am Geriatr Soc; 2021 Dec; 69(12):3602-3607. PubMed ID: 34499744
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Multicenter Experience using Ledipasvir/Sofosbuvir ± RBV to Treat HCV GT 1 Relapsers after Simeprevir and Sofosbuvir Treatment.
    Aqel B; Leise M; Vargas HE; Watt KD; Keaveny AP; Zhang N; Zhang N; Pungpapong S
    Ann Hepatol; 2018 Aug; 17(5):815-821. PubMed ID: 30145562
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Real-world effectiveness and safety of sofosbuvir/velpatasvir and ledipasvir/sofosbuvir hepatitis C treatment in a single centre in Germany.
    Buggisch P; Wursthorn K; Stoehr A; Atanasov PK; Supiot R; Lee J; Ting J; Petersen J
    PLoS One; 2019; 14(4):e0214795. PubMed ID: 30946776
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sofosbuvir and ledipasvir are associated with high sustained virologic response and improvement of health-related quality of life in East Asian patients with hepatitis C virus infection.
    Younossi ZM; Stepanova M; Henry L; Han KH; Ahn SH; Lim YS; Chuang WL; Kao JH; Nguyen KV; Lai CL; Chan HL; Wei L
    J Viral Hepat; 2018 Dec; 25(12):1429-1437. PubMed ID: 29974665
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and Safety of Ledispavir/Sofosbuvir with or without Ribavirin in patients with Decompensated Liver Cirrhosis and Hepatitis C Infection: a Cohort Study.
    Gheorghe LS; Preda C; Iliescu L; Istratescu D; Chifulescu AE; Pop CS; Trifan A; Stanciu C; Diculescu M; Voiosu T; Baicus C; Tugui L; Iacob S; Tieranu C; Meianu C; Manuc M
    J Gastrointestin Liver Dis; 2020 Sep; 29(3):385-390. PubMed ID: 32919421
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Real-world effectiveness of ledipasvir/sofosbuvir in 4,365 treatment-naive, genotype 1 hepatitis C-infected patients.
    Backus LI; Belperio PS; Shahoumian TA; Loomis TP; Mole LA
    Hepatology; 2016 Aug; 64(2):405-14. PubMed ID: 27115523
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effectiveness of Sofosbuvir, Ledipasvir/Sofosbuvir, or Paritaprevir/Ritonavir/Ombitasvir and Dasabuvir Regimens for Treatment of Patients With Hepatitis C in the Veterans Affairs National Health Care System.
    Ioannou GN; Beste LA; Chang MF; Green PK; Lowy E; Tsui JI; Su F; Berry K
    Gastroenterology; 2016 Sep; 151(3):457-471.e5. PubMed ID: 27267053
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sofosbuvir-based regimens in clinical practice achieve SVR rates closer to clinical trials: results from ERCHIVES.
    Butt AA; Yan P; Shaikh OS; Chung RT; Sherman KE;
    Liver Int; 2016 May; 36(5):651-8. PubMed ID: 26616353
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effectiveness, safety and clinical outcomes of direct-acting antiviral therapy in HCV genotype 1 infection: Results from a Spanish real-world cohort.
    Calleja JL; Crespo J; Rincón D; Ruiz-Antorán B; Fernandez I; Perelló C; Gea F; Lens S; García-Samaniego J; Sacristán B; García-Eliz M; Llerena S; Pascasio JM; Turnes J; Torras X; Morillas RM; Llaneras J; Serra MA; Diago M; Rodriguez CF; Ampuero J; Jorquera F; Simon MA; Arenas J; Navascues CA; Bañares R; Muñoz R; Albillos A; Mariño Z;
    J Hepatol; 2017 Jun; 66(6):1138-1148. PubMed ID: 28189751
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical effectiveness of pharmacist-led versus conventionally delivered antiviral treatment for hepatitis C virus in patients receiving opioid substitution therapy: a pragmatic, cluster-randomised trial.
    Radley A; de Bruin M; Inglis SK; Donnan PT; Hapca A; Barclay ST; Fraser A; Dillon JF
    Lancet Gastroenterol Hepatol; 2020 Sep; 5(9):809-818. PubMed ID: 32526210
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment adherence and virological response rates in hepatitis C virus infected persons treated with sofosbuvir-based regimens: results from ERCHIVES.
    Butt AA; Yan P; Shaikh OS; Chung RT; Sherman KE;
    Liver Int; 2016 Sep; 36(9):1275-83. PubMed ID: 26928927
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Proton pump inhibitor usage reduces sustained viral response rates for veterans with HIV/HCV coinfection on ledipasvir/sofosbuvir: a real-world study from a multicentre VA cohort.
    Lee TH; Chan A; Bryan W; Park L; Hashem M; Townsend M; Moylan C; Britt R; Choi S; Naggie S
    J Viral Hepat; 2021 Apr; 28(4):630-636. PubMed ID: 33378562
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effectiveness and safety of ledipasvir/sofosbuvir±ribavirin in the treatment of HCV infection: The real-world HARVEST study.
    Flisiak R; Łucejko M; Mazur W; Janczewska E; Berak H; Tomasiewicz K; Mozer-Lisewska I; Kozielewicz D; Gietka A; Sikorska K; Wawrzynowicz-Syczewska M; Nowak K; Zarębska-Michaluk D; Musialik J; Simon K; Garlicki A; Pleśniak R; Baka-Ćwierz B; Olszok I; Augustyniak K; Stolarz W; Białkowska J; Badurek A; Piekarska A
    Adv Med Sci; 2017 Sep; 62(2):387-392. PubMed ID: 28554119
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment of hepatitis C virus recurrence after transplantation with sofosbuvir/ledipasvir: The role of ribavirin.
    Globke B; Raschzok N; Teegen EM; Pratschke J; Schott E; Eurich D
    Transpl Infect Dis; 2017 Feb; 19(1):. PubMed ID: 27943544
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety and efficacy of sofosbuvir plus ledipasvir with and without ribavirin for chronic HCV genotype-1 infection: a systematic review and meta-analysis.
    Ahmed H; Elgebaly A; Abushouk AI; Hammad AM; Attia A; Negida A
    Antivir Ther; 2017; 22(5):369-379. PubMed ID: 27588749
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Persistence of Virologic Response after Liver Transplant in Hepatitis C Patients Treated with Ledipasvir / Sofosbuvir Plus Ribavirin Pretransplant.
    Yoshida EM; Kwo P; Agarwal K; Duvoux C; Durand F; Peck-Radosavljevic M; Lilly L; Willems B; Vargas H; Kumar P; Brown RS; Horsmans Y; De-Oertel S; Arterburn S; Dvory-Sobol H; Brainard DM; McHutchison JG; Terrault N; Rizzetto M; Müllhaupt B
    Ann Hepatol; 2017; 16(3):375-381. PubMed ID: 28425407
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and Safety of Ledipasvir/Sofosbuvir with and without Ribavirin in Patients with Chronic Hepatitis C Virus Genotype 1 Infection: a meta-analysis.
    Tao T; Jiang X; Chen Y; Song Y
    Int J Infect Dis; 2017 Feb; 55():56-71. PubMed ID: 28040553
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The safety and efficacy of ledipasvir/sofosbuvir with or without ribavirin in the treatment of orthotopic liver transplant recipients with recurrent hepatitis C: real-world data.
    Pyrsopoulos N; Trilianos P; Lingiah VA; Fung P; Punnoose M
    Eur J Gastroenterol Hepatol; 2018 Jul; 30(7):761-765. PubMed ID: 29481384
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effectiveness of sofosbuvir-based regimens in genotype 1 and 2 hepatitis C virus infection in 4026 U.S. Veterans.
    Backus LI; Belperio PS; Shahoumian TA; Loomis TP; Mole LA
    Aliment Pharmacol Ther; 2015 Sep; 42(5):559-73. PubMed ID: 26113432
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Real-world effectiveness of daclatasvir plus sofosbuvir and velpatasvir/sofosbuvir in hepatitis C genotype 2 and 3.
    Belperio PS; Shahoumian TA; Loomis TP; Mole LA; Backus LI
    J Hepatol; 2019 Jan; 70(1):15-23. PubMed ID: 30266283
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.